Stockscreener 앱 받기
2.79
7.31%
-0.22
시간 외 거래:
2.75
-0.04
-1.43%
전일 마감가:
$3.01
열려 있는:
$2.91
하루 거래량:
2.49M
Relative Volume:
1.89
시가총액:
$451.83M
수익:
-
순이익/손실:
$-274.18M
주가수익비율:
-1.1008
EPS:
-2.5346
순현금흐름:
$-198.33M
1주 성능:
+7.72%
1개월 성능:
+52.46%
6개월 성능:
+259.44%
1년 성능:
-76.17%
1일 변동 폭
$2.7201
$2.955
1주일 범위
$2.40
$3.25
52주 변동 폭
$0.611
$14.09
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
260 ARSENAL PLACE, SUITE 1, WATERTOWN
NMRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.79 | 487.46M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-27 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-09-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-04-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-03-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-10-10 | 개시 | BofA Securities | Buy |
| 2023-10-10 | 개시 | Guggenheim | Buy |
| 2023-10-10 | 개시 | JP Morgan | Overweight |
| 2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-10 | 개시 | Stifel | Buy |
| 2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Can Neumora Therapeutics Inc. stock maintain growth trajectory2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
How moving averages guide Neumora Therapeutics Inc. tradingPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Neumora Therapeutics accelerates investor outreach in Boston and New York - Traders Union
Neumora Therapeutics to Participate in Upcoming Conferences in November - The Manila Times
Real time social sentiment graph for Neumora Therapeutics Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - newser.com
Neumora (Nasdaq: NMRA) to participate in two November conferences; webcasts available - Stock Titan
Heatmap analysis for Neumora Therapeutics Inc. and competitors2025 Investor Takeaways & Daily Price Action Insights - newser.com
Why Neumora Therapeutics Inc. stock is a must watch in 20252025 Valuation Update & Growth-Oriented Investment Plans - newser.com
Can a trend reversal in Neumora Therapeutics Inc. lead to recoveryPortfolio Performance Report & Daily Volume Surge Signals - newser.com
Is Neumora Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
What risks investors should watch in Neumora Therapeutics Inc. stockEarnings Overview Report & Daily Technical Stock Forecast Reports - newser.com
Neumora Therapeutics, Inc. (NMRA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Is Neumora Therapeutics Inc. stock entering bullish territoryJuly 2025 Review & Long Hold Capital Preservation Plans - newser.com
Will Neumora Therapeutics’ (NMRA) Novel Drug Pipeline Define Its Competitive Edge in Biotech? - Sahm
What momentum shifts mean for Neumora Therapeutics Inc.July 2025 WrapUp & Expert Curated Trade Setup Alerts - newser.com
Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies - MSN
Regression analysis insights on Neumora Therapeutics Inc. performance2025 Year in Review & Daily Profit Maximizing Tips - newser.com
Neumora Therapeutics Inc. stock outlook for YEARJuly 2025 Review & Free Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-31 04:44:03 - newser.com
Published on: 2025-10-31 03:53:08 - newser.com
Neumora Therapeutics, Inc. (NMRA) stock price, news, quote and history - Yahoo! Finance UK
Neumora Therapeutics (NMRA): Evaluating Valuation Following Dual Pipeline Advances in Psychiatry and Obesity - Yahoo Finance
Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating - Insider Monkey
Arch Venture Partners Xii, Llc Acquires 1,915,700 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Director Kristina Burow Acquires 1,915,700 Shares - MarketBeat
Neumora Therapeutics Stock (NMRA) Opinions on Obesity Drug Data Release - Quiver Quantitative
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Breakthrough for Major Depressive Disorder - MSN
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Game-Changer for Depression Treatment - MSN
Guggenheim upgrades Neumora Therapeutics, Inc. (NMRA) to a Buy - The Globe and Mail
Neumora Therapeutics Advances MDD Treatment with Long-term Study - MSN
Neumora to initiate phase 1 study of oral obesity pill - MSN
Neumora Therapeutics Insider Bought Shares Worth $4,999,977, According to a Recent SEC Filing - MarketScreener
Neumora Therapeutics price target raised to $8 from $6 at Needham - MSN
Published on: 2025-10-30 01:21:45 - newser.com
Major Stakeholders Make Bold Moves in Neumora Therapeutics! - TipRanks
[Form 4] Neumora Therapeutics, Inc. Insider Trading Activity - Stock Titan
Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $8.00 - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Is Neumora Therapeutics Inc. stock a top pick in earnings season2025 Buyback Activity & Safe Entry Zone Tips - fcp.pa.gov.br
Neumora Therapeutics’ NMRA-323511 Study: A Potential Breakthrough in Alzheimer’s Treatment - MSN
14 Stocks Under $5 with Highest Upside Potential - Insider Monkey
Needham Maintains Neumora Therapeutics (NMRA) Buy Recommendation - MSN
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $5 to $18 - 富途牛牛
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Neumora Therapeutics Inc 주식 (NMRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC | 10% Owner |
Oct 27 '25 |
Buy |
2.61 |
1,915,700 |
4,999,977 |
6,046,907 |
| ARCH Venture Partners X, LLC | 10% Owner |
Oct 27 '25 |
Buy |
2.61 |
1,915,700 |
4,999,977 |
6,046,907 |
1.45%
0.86%
자본화:
|
볼륨(24시간):